LONDEN & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, een internationale organisatie voor uitbesteed onderzoek, heeft samen met Veras Research en LSK Global Pharma Services een seminar over de sector georganiseerd in de Britse ambassade in Tokyo.
Het evenement ‘Exploring Options for Local and Global Outsourcing in the Pharmaceutical and Biotech Industries’ was gericht op de ontwikkeling van oncologisch onderzoek en andere cruciale medische velden. Daarnaast was er aandacht voor dienstverlening op de Japanse markt.
Chiltern heeft een lange geschiedenis van samenwerkingen met Japanse bedrijven en sinds 2003 bezoeken werknemers van het bedrijf met grote regelmaat de ambassade in Tokyo. Het seminar ondersteunt de inzet van Chiltern en Veras voor groei in Azië, met een speciale focus op Japan.
Chiltern and Partners Hold Seminar at the British Embassy in Japan
LONDON & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, a leading, global contract research organization (CRO), hosted an industry seminar at the British Embassy in Tokyo, Japan, on Oct. 6, 2015, alongside Veras Research and LSK Global Pharma Services.
The event, “Exploring Options for Local and Global Outsourcing in the Pharmaceutical and Biotech Industries,” focused on development insights for oncology trials, other key therapeutic areas, medical devices and functional service provision relative to the Japanese market.
Chiltern has a long history of partnering with a significant number of Japanese companies, and its team members have regularly visited the embassy in Tokyo since 2003. The seminar supported Chiltern’s and Veras’ commitment to growing in Asia, with a specific focus in Japan.
“By working with Veras and LSK, we strengthen Chiltern’s already extensive footprint in Japan,” said Stuart McGuire, executive vice president, global business development, at Chiltern. “We are grateful for the support from UK Trade & Investment and the British Embassy in Tokyo for their part in helping us create such an exciting forum for discussion.”
McGuire co-hosted the event and was joined by other members of the Chiltern leadership team, including Nick Thornton, chairman, and Roger Hunter, executive vice president, scientific affairs and strategic development.
Chiltern has robust expertise in the conduct of global clinical trials, specifically in the fields of oncology, respiratory, anti-infectives, dermatology and ophthalmology, with special capabilities in clinical analytics and medical device and diagnostics. Its quality of service, value and global presence are important for many companies looking to involve Japan in their clinical development programs.
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 3,700 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. VisitChiltern.com to learn more about responsive solutions that are Designed Around You ®.
Lea Studer, +1 308-237-5567